The Future of Breast Lesion Localization Market

The breast lesion localization market is primarily driven by the rising incidence of breast cancer, the increasing number of breast cancer screening programs, and improved reimbursement scenario. This, in turn, is attributed to the growth in the aging population and changing lifestyles, which have increased the overall possibility of cancer occurrence. 

The impact of the COVID-19 pandemic and the lockdown it triggered is clearly visible in various industries, including the breast lesion localization market. The overall growth of various sectors has been heavily impacted, specifically in countries with a high incidence rate of COVID-19, such as China, the US, and several European countries (Russia, Italy, and Spain, among others). 

Thus, screening, diagnostic exams, and surgical procedures are being restricted or postponed at hospitals and breast centers, especially in the case of lower-risk patients, considering that most screening and localization procedures require very close contact between patients and caregivers. 

𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=35768623 

Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement. 

With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors (a type of adult stem cell at the root of many breast cancers) and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. 

According to the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. In contrast, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above. 

With the presence of stringent regulatory requirements for product approval, players operating in the breast lesion localization methods (specially radioisotope localization) market need to obtain nuclear regulatory clearance from the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. 

Key Market Players breast lesion localization market are Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US).